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Objective: Pro- and anti-inﬂammatory mediators, such as IL-1b and IL1Ra, are produced by joint tissues
in osteoarthritis (OA), where they may contribute to pathogenesis. We examined whether inﬂammatory
events occurring within joints are reﬂected in plasma of patients with symptomatic knee osteoarthritis
(SKOA).
Design: 111 SKOA subjects with medial disease completed a 24-month prospective study of clinical and
radiographic progression, with clinical assessment and specimen collection at 6-month intervals. The
plasma biochemical marker IL1Ra was assessed at baseline and 18 months; other plasma biochemical
markers were assessed only at 18 months, including IL-1b, TNFa, VEGF, IL-6, IL-6Ra, IL-17A, IL-17A/F, IL-
17F, CRP, sTNF-RII, and MMP-2.
Results: In cross-sectional studies, WOMAC (total, pain, function) and plasma IL1Ra were modestly
associated with radiographic severity after adjustment for age, gender and body mass index (BMI). In
addition, elevation of plasma IL1Ra predicted joint space narrowing (JSN) at 24 months. BMI did associate
with progression in some but not all analyses. Causal graph analysis indicated a positive association of
IL1Ra with JSN; an interaction between IL1Ra and BMI suggested either that BMI inﬂuences IL1Ra or that
a hidden confounder inﬂuences both BMI and IL1Ra. Other protein biomarkers examined in this study
did not associate with radiographic progression or severity.
Conclusions: Plasma levels of IL1Ra were modestly associated with the severity and progression of SKOA
in a causal fashion, independent of other risk factors. The ﬁndings may be useful in the search for
prognostic biomarkers and development of disease-modifying OA drugs.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.to: M. Attur, Division of
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1-212-598-6168.
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Osteoarthritis (OA), the most common adult joint disease, is
increasing in frequency and severity, with an estimated
US prevalence of over 25 million affected adults1. Disease pro-
gression is associated with cartilage degradation, synovial prolif-
eration and bony changes, including osteophytes, subchondral
sclerosis and bone marrow lesions.
Identiﬁcation of patients at risk for disease progression remains
a challenge, particularly since routine radiography is an insensitivetd. All rights reserved.
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abnormalities. There is consensus that development of disease-
modifying treatment of OA would be aided by validated bio-
markers, which identify patients at risk for progressive disease
development2. Indeed, the quest for improved imaging markers
(including X-ray) is an active area of investigation. To date, most
biochemical biomarker studies have focused on degradation or
synthetic products of cartilage, bone or synovium and have yielded
mixed results3e7. Conventional inﬂammatory markers such as C-
reactive protein (CRP) have not consistently been associated with
severity or progression of knee OA2,8.
While traditionally considered a non-inﬂammatory joint dis-
ease, it is now well-appreciated that inﬂammatory mediators are
produced by articular tissues in OA and have been implicated in
disease pathogenesis9e12. Indeed, cytokines and prostaglandins
produced by cartilage promote cartilage degeneration, while sy-
novitis has been associated with greater risk of cartilage loss in
patients with knee OA13,14. Emerging literature indicates that local
inﬂammation within OA joint tissues can be reﬂected in elevated
plasma biomarkers8. Work by Robinson and associates11, for
example, has revealed increased inﬂammatory proteins in sera of
OA patients with joint effusions compared to controls, including
interleukin-1 beta (IL-1b), IL-1 receptor antagonist (IL1Ra), IL-6,
monocyte chemo-attractant protein-1 (MCP-1), monocyte
interferon-gamma-inducible protein (MIG), vascular endothelial
growth factor (VEGF), and granulocyte-macrophage colony-stim-
ulating factor (GM-CSF). The levels of these cytokines were higher
in OA synovial ﬂuid than sera, consistent with their origin from
joint tissues9e12. We have recently reported that circulating blood
leukocytes in patients with knee OA exhibit increased IL-1b gene
expression, consistent with exposure to cytokines produced by OA
joint tissues15. Increased leukocyte IL-1b expressionwas associated
with increased knee pain and predicts risk for progression of
symptomatic knee OA (SKOA)15.
In the current study, we examined demographic and anthro-
pometric features as well as plasma levels of a panel of inﬂam-
matory markers in a 2-year prospective analysis of radiographic
progression in patients with SKOA. Our data indicate that among 12
candidate markers studied, plasma IL1Ra is a potential prognostic
biomarker of radiographic progression in OA.
Patients and methods
Patients
As part of an NIH-funded study, 183 patients with SKOA were
assessed at baseline and enrolled in a 24-month prospective study
at the NYU Hospital for Joint Diseases (“NYUHJD SKOA progression
cohort”). All patients complained of pain in the signal knee, met
American College of Rheumatology (ACR) clinical symptomatic
criteria, and had KellgreneLawrence (KL) grade 116,17. Patients
were excluded if they had any other form of arthritis; body mass
index (BMI) > 33 kg/m2; any disorder requiring the use of systemic
corticosteroids; history of bilateral knee replacements; major
comorbidities including diabetes mellitus, noncutaneous cancer
within 5 years of screening, chronic hepatic or renal disease, chronic
infectious disease, or congestive heart failure; or had received a
hyaluronan and/or corticosteroid injection to the affected knee
within 3 months of screening. All patients were examined by one of
two NYUHJD investigators (SK, JS) every 6months; 146 patients had
completed the 24-month observation period at the time of this
analysis. Radiographic assessments at baseline and 24 months
included bilateral (signal and non-signal knee) KL determination,
quantitativemeasurement of joint spacewidth (JSW), all performed
by a musculoskeletal radiologist (LR) blinded to patientinformation. Baseline clinical information and radiographic images
of joints other than the knee are not available for these patients.
Prior to study initiation, the protocol was approved by the IRB of
NYU School of Medicine, and written informed consent was ob-
tained from all study participants.
Knee radiographs
All NYUHJD SKOA patients underwent standardized weight-
bearing ﬁxed-ﬂexion posteroanterior knee radiographs using the
SynaFlexer™ X-ray positioning frame (Synarc). X-rays were scored
for KL grade 0e4, and medial and lateral JSW. Radiographic pro-
gression (JSN e joint space narrowing) was deﬁned as narrowing of
medial JSW in signal knee between baseline and 24-month follow-
up. JSW was measured at the narrowest portion of the joint space
via electronic calipers linked to computer monitor.
Sample collection
Non-fasting blood samples were collected at baseline when
patients came for knee radiographs, and at 18-month clinical visit,
in pyrogen-free heparinized tubes for isolation of plasma. After
drawing, the tubes were inverted several times, immediately
placed on ice for 30 min, and then spun at 3000 rpm for 15 min at
4C to separate the plasma. Plasma samples were immediately
aliquoted and stored at 70C for future use.
Plasma cytokine determination
At baseline, we determined only IL1Ra and no other biomarkers,
because of limited plasma samples. More plasma was available at
18 months, so additional plasma protein biomarkers were assayed
e IL-1b, tumor necrosis factor a (TNFa), IL1Ra, VEGF, IL-6, soluble IL-
6 receptor a (sIL-6Ra), IL-17 isoforms (IL-17A, IL-17A/F, IL-17F), CRP,
soluble TNF receptor II (sTNF-RII) and matrix metalloproteinase-2
(MMP-2) e using the highly sensitive Erenna Immunoassay sys-
tem (Singulex, Inc.), based upon single molecule counting tech-
nology, as described18. The limits of detection (pg/mL; least amount
of analyte per sample that could be detected but not necessarily
quantitated as an exact value), limits of quantiﬁcation (pg/mL; least
amount of analyte per sample that could be quantitatively deter-
mined with suitable precision) and average coefﬁcients of variation
of the assays, respectively, were: IL-1b (0.03, 0.20, 7%); TNFa (0.02,
0.20, 7%); IL1Ra (1.64, 3.91, 7%); VEGF (0.06, 0.39, 6%); IL-6 (0.01,
0.10, 6%); IL-6Ra (0.01, 0.39, 8%); IL-17A (0.01, 0.10, 13%); IL-17A/F
(0.10, 0.59, 6%); IL-17F (0.69, 3.13, 9%); CRP (0.12, 1.95, 7%), sTNF-
RII (0.01, 0.04, 9%); MMP-2 (0.588, 3.91, 6%).
Statistical methods
We assessed associations and discrimination/predictive power
of single biomarkers with outcomes of baseline and 24-month KL
severity (KL1/2 vs KL3/4) and radiographic JSN over 24 months
using the following statistical tools:
1) Analysis of Fisher's partial correlations (adjusted for age, gender,
BMI) of biomarkers with continuous JSN outcome variables.
2) Assessing predictivity of biomarkers for dichotomized outcome
variables (e.g., KL1/2 vs KL3/4) with the area under receiver
operating characteristic curve (AUC) and logistic regression
(either unadjusted or adjusted for age, gender, BMI), as
described19,20.
3) Comparing the means of a continuous outcome variable (e.g.,
JSN) for groups of patients deﬁned based on biomarker values
using Student's two-tailed t-test.
M. Attur et al. / Osteoarthritis and Cartilage 23 (2015) 1915e1924 1917We used 5% alpha level and corrected for multiple comparisons
using the approach of Benjamini and Hochberg for assessing sta-
tistical signiﬁcance21.
For the radiographic JSN outcome variable, we deﬁned non-
progressors as having JSN  0.0 mm/24 months, and three sub-
groups of progressors with JSN >0.0 or >0.2 mm (“slow-pro-
gressors”), or >0.5 mm (“fast-progressors”) per 24 months. These
thresholds were based on Emrani et al.22 and recommendations of
The European Society for Clinical and Economic Aspects of Osteo-
porosis and Osteoarthritis (ESCEO)23.
For building predictive multivariable models of a dichotomized
outcome variable [medial JSN and radiographic severity (KL1/2 vs
KL3/4)] based on multiple biomarkers, we used support vector
machines24. For measuring predictive performance, we used the
AUC. For estimating predictivity of multivariate models, we used
10-fold stratiﬁed cross-validation repeated with 100 different splits
of data into 10-folds25. We used strict multiple comparison control
procedures to ensure no type I error inﬂation. All tests were cor-
rected using the Bonferroni correction.
For causal graph analysis, we have used the Fast Causal Inference
(FCI) algorithm26. This method discovers the causal graph consis-
tent with the data and also identiﬁes hidden confounding. The al-
gorithm has been proven to be correct (i.e., to identify underlying
causal structure) under very broad distributional assumptions. No
data manipulation of any kind (e.g., transformation, imputation,
thresholding) was applied for this analysis, so that it was not biased
toward particular causal hypotheses. We used implementation of
the FCI algorithm in the TETRAD software package (http://www.
phil.cmu.edu/projects/tetrad/) with Fisher's z-test and 0.05 signif-
icance level.Results
NYUHJD symptomatic knee OA (SKOA) patient cohort
Baseline demographic and clinical characteristics of SKOA are
summarized in Table I. Mean (± standard deviation) age of patients
was 62.5 (±10.5) years; 64.5% were female; mean BMI was 26.7Table I
Comparison of demographic and clinical characteristics of patients with SKOA an
Variable Baseline (N ¼ 180
Age, years (mean ± SD) 62.6 ± 10.5
Gender F ¼ 116; M ¼ 64
BMI 26.7 ± 3.5
RACE Caucasians (n ¼ 1
Blacks (n ¼ 41)
Asians (n ¼ 13)
Ethnicity Non-Hispanic (n ¼
Hispanic (n ¼ 25)
WOMAC total 114.6 ± 67.8 (0e2
VAS 43.4 ± 28.6 (0e10
Percent KL distribution (n ¼ 146) KL1/2 (30%)
KL3/4 (60%)
IL1Ra pg/ml (n ¼ 146) 316.01 ± 202.46 (
MMP-2 ng/ml e
IL-1b pg/ml e
TNFa pg/ml e
sTNF-RII pg/ml e
IL-6 pg/ml e
IL-6R alpha pg/ml e
IL-17A pg/ml e
IL-17F pg/ml e
IL-17A/F pg/ml e
CRP ng/ml e
Abbreviations: BMI, body mass index; WOMAC, Western Ontario and McMaster
* Data are presented as mean ± SD unless otherwise indicated; data range is p(±3.5). Mean total WOMAC score (0e300 scale) was 114.6 (±67.8)
and mean pain score on a 0e100 visual analog scale (VAS) was 43.4
(±28.6).Biomarkers associated with SKOA radiographic severity (KL1/2 vs
KL3/4)
Baseline IL1Ra and clinical markers were assessed for associa-
tion with baseline radiographic severity in SKOA subjects. IL1Ra
was measured at two time points, baseline and 18 months. Eleva-
tion of baseline IL1Ra was associated statistically signiﬁcant with
severity in bivariate analysis (P < 0.04; [Fig. 1(A)], Table II), but did
not reach signiﬁcance when adjusted for multiple comparisons and
for age, gender and BMI (KL1/2 vs KL3/4 with AUC ¼ 0.59;
P ¼ 0.105). Repeat measurements of IL1Ra at 18 months conﬁrmed
these ﬁndings and were highly signiﬁcant: in a logistic regression
model, plasma IL1Ra was associated statistically signiﬁcantly with
radiographic severity at baseline after adjustment for age, gender
and BMI (AUC ¼ 0.67; P ¼ 0.018).
IL1Ra measured at 18 months was also associated statistically
signiﬁcant with 24-month radiographic severity (AUC ¼ 0.69;
95% CI 0.59e0.83; P ¼ 0.004) [Fig. 1(A), Table II]. Furthermore,
there is a signiﬁcant correlation between plasma IL1Ra levels at
baseline and 18 months (r ¼ 0.37; P ¼ 0.001). In contrast, base-
line plasma IL1Ra levels did not correlate with 18 month plasma
IL-1b (r ¼ 0.11; P ¼ 0.31) [Fig. 1(B)]. In contrast to IL1Ra, no other
plasma biomarkers tested showed signiﬁcant association with
baseline radiographic severity (Table II). Several biomarkers
(VEGF, CRP, sTNF-RII) were modestly associated with severity,
but these associations were not independent of age, gender, and
BMI.
We next tested multivariate predictive models with baseline
plasma protein (IL1Ra) biomarkers alone and in combination with
clinical markers (WOMAC and VAS pain), age, gender and BMI.
The resulting predictivity of radiographic severity for IL1Ra alone
was AUC ¼ 0.59 (95% CI 0.49e0.70; P ¼ 0.045) and for clinical
biomarkers alone AUC ¼ 0.59 (95% CI 0.49e0.70; P ¼ 0.045). With
combination of both clinical and baseline IL1Ra the predictivity ofd of plasma biomarkers levels at baseline and 18 months*
) 18 months (N ¼ 125)
63.3 þ 9.73
(Female 64.5%) F ¼ 78; M ¼ 47 (Female 62.0%)
26.5 ± 3.6
26), Caucasians (n ¼ 84),
Blacks (n ¼ 30)
Asians (n ¼ 11)
155) Non-Hispanic (n ¼ 114)
Hispanic (n ¼ 11)
94.6) 93.03 ± 66.38 (0e267.9)
0) 32.7 ± 26.82 (0e100)
e
36.70e1290.0) 265.99 ± 112.05 (83.0e676.0)
83.3 ± 63.5 (33.0e399.0)
0.44 ± 0.55 (0.08e3.5)
2.41 ± 2.89 (0.4e20.50)
3455 ± 1470 (1451e10,983)
1.99 ± 2.05 (0.1e12.1)
25.49 ± 9.45 (8.0e59.0)
0.39 ± 1.08 (0.0e10.70)
41.24 ± 162.8 (4.4e1597)
2.92 ± 3.04 (0.2e23.60)
1513 ± 2864 (25e23,997)
Universities Arthritis Index; VAS, visual analog scale.
rovided in parentheses below each value.
Fig. 1. Association of baseline IL1Ra with radiographic severity and progression in SKOA patients. A) Distribution of log-transformed plasma baseline and 18 month IL1Ra
between KL1/2 (n ¼ 43) vs KL3/4 (n ¼ 89) radiographic severity groups. Data are presented as box plots; the lines within the boxes represent the median, and the lines outside the
boxes represent the twenty-ﬁfth and seventy-ﬁfth percentiles. B) Correlation of log-transformed baseline IL1Ra and 18 month IL1Ra and with 18 month plasma IL-1b. C) Correlation
of log-transformed baseline IL1Ra with medial JSN (n ¼ 109). D) Distribution of plasma baseline between radiographic non-progressors (JSN < 0.0 mm; n ¼ 39) and progressors
[JSN > 0.0 (n ¼ 72); 0.2 (n ¼ 64) and 0.5 mm (n ¼ 44)] over 24 months. Data are presented as box plots; the lines within the boxes represent the median, and the lines outside the
boxes represent the twenty-ﬁfth and seventy-ﬁfth percentiles. R and P values are indicated in the ﬁgures. Abbreviations: IL1Ra, interleukin 1 receptor antagonist; KL, Kell-
greneLawrence score; JSN, joint space narrowing.
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P ¼ 0.02. Table III shows the parameters derived from ROC curves
such as pre-speciﬁed sensitivity and speciﬁcity of baseline IL1Ra
in discriminating OA patients with severe-KL3/4 from those with
KL1/2.Table II
Relationship of baseline and 18-month biomarkers to baseline radiographic severity (KL
Markers AUC P-values P-values adjusted for
multiple comparisonsz
GLM-based (Logistic regre
(No adjustment) Age
Baseline*
IL1RA 0.59 0.042 0.105 0.048 0.083
Age 0.63 0.011 0.105
Gender 0.60 0.018 0.105
BMI 0.55 0.182 0.253
18 monthsy
IL1RA 0.67 0.001 0.018 0.001 0.006
VEGF 0.60 0.042 0.105 0.127 0.229
IL-17F 0.41 0.053 0.107 0.563 0.686
IL-17A/F 0.46 0.255 0.306 0.217 0.052
IL-17A 0.54 0.269 0.306 0.724 0.671
IL-1Beta 0.45 0.163 0.239 0.832 0.656
IL-6 0.56 0.152 0.237 0.227 0.388
TNF-alpha 0.46 0.267 0.306 0.941 0.720
CRP 0.61 0.024 0.105 0.241 0.447
sTNF-RII 0.59 0.039 0.105 0.233 0.515
IL-6R alpha 0.48 0.345 0.345 0.936 0.715
MMP2 0.59 0.056 0.107 0.103 0.197
P-values signiﬁcant at 5% alpha level are shown in bold.
Abbreviations: KL, KellgreneLawrence; AUC, area under receivereoperator curve.
* Baseline: association of biomarkers measured at baseline with SKOA severity at base
y 18 Months: association of biomarkers measured at 18 months with SKOA severity a
dictivity for radiographic severity, we used the area under the receiver operating charact
for each group. Generalized Linear Model (GLM) -based (logistic regression) P-values are p
three covariates: age, gender and BMI.
z Adjusted using Bonferroni correction.Baseline plasma IL1Ra predicts radiographic progression by medial
JSN
From our cohort of patients who completed the 24-month study
(n¼ 146), 18 patients who had predominantly lateral compartment1/2 vs KL3/4) in SKOA patients
ssion) KL1/2: Mean
(±SD)
KL3/4: Mean
(±SD)
Gender BMI Age, gender, BMI
0.037 0.105 0.121 262.25 (120.09) 322.90 (183.25)
58.90 (11.82) 63.73 (9.14)
0.26 (0.45) 0.45 (0.5)
26.36 (3.82) 27.25 (3.13)
0.0002 0.003 0.005 229.13 (79.13) 290.14 (106.04)
0.077 0.203 0.238 94.63 (40.66) 109.21 (60.06)
0.476 0.682 0.719 29.45 (35.39) 45.26 (190.24)
0.197 0.186 0.043 2.62 (1.46) 3.33 (3.81)
0.600 0.828 0.679 0.34 (0.6) 0.41 (1.23)
0.897 0.872 0.624 0.40 (0.3) 0.39 (0.45)
0.217 0.295 0.426 1.83 (1.59) 2.26 (2.05)
0.851 0.978 0.752 2.39 (2.07) 2.36 (2.90)
0.192 0.379 0.550 1191.71 (2020.03) 1775.25 (3193.1)
0.238 0.284 0.570 3254.87 (1522.5) 3572.68 (1364.1)
0.774 0.755 0.778 25.90 (7.9) 25.77 (8.96)
0.114 0.132 0.268 73.39 (46.41) 92.87 (73.21)
line.
t baseline (radiographs not available at 18 months). For measuring biomarker pre-
eristic (ROC) curve. The mean and standard deviation of each biomarker is provided
rovided without adjustment and after adjusting individually and in combination for
Table III
Pre-computed sensitivity and speciﬁcity of pre-cut-off baseline plasma IL1Ra on
predicting radiographic progressors
Sensitivity Baseline IL1RA
(pg/ml) cutoff
Speciﬁcity
JSN  0 vs. JSN > 0 mm 0.5 298.9 0.72
0.6 245.0 0.64
0.7 216.7 0.44
0.8 168.9 0.15
0.9 155.0 0.15
JSN  0 vs. JSN > 0.2 mm 0.5 298.9 0.72
0.6 248.3 0.64
0.7 213.3 0.41
0.8 168.9 0.15
0.9 155.0 0.15
JSN  0 vs. JSN > 0.5 mm 0.5 336.7 0.79
0.6 285.0 0.69
0.7 223.3 0.54
0.8 188.3 0.26
0.9 163.3 0.15
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differ with respect to risk factors for disease severity and progres-
sion27. In addition, 17 SKOA patients who had JSW ¼ 0 mm at
baseline were also excluded as they could not mechanically
“progress.” We restricted our association analysis to patients
(n ¼ 111) with medial compartment disease. While an association
of biomarkers with severity may provide insight into disease
mechanisms, amore essential function for a candidate biomarker in
OA would be to predict disease progression. As shown in Fig. 1(C)
and Table IV, baseline IL1Ra had modest correlation (r ¼ 0.24;
P ¼ 0.01) with medial JSN at 24 months and did not correlate with
lateral JSN (r ¼ 0.012; P ¼ 0.89). After adjustment for age, gender
and BMI, plasma IL1Ra at baseline retained positive correlation
(r ¼ 0.193; P ¼ 0.047) with medial JSN and not lateral JSN at 24
months. In contrast, other biomarkers did not correlatewithmedial
JSN (data not shown).
Bivariate and multivariate predictors of JSN
In a bivariate model, we further assessed plasma IL1Ra as a
predictor of radiographic progression. As shown in Table V, SKOA
patients with baseline IL1Ra levels above the median progressed
more rapidly than patients with baseline IL1Ra at or below median
level (medial JSW 0.36 mm vs 0.70 mm/24 months, P ¼ 0.041). Box
plot distributions of baseline IL1Ra between non-progressors
(JSN < 0.0 mm) and progressors (JSN > 0.0; >0.2 and 0.5 mm) are
shown in Fig. 1(D). We also examined increased BMI as a risk factor
for development of OA and progression28,29. We did not observe
signiﬁcant difference between the two BMI groups (below and
above median BMI) with respect to mean medial JSW at 24 months
(Table V).
We next examined whether IL1Ra and BMI predicted SKOA
progressors vs non-progressors, as assessed by changes in minimalTable IV
Medial and lateral JSW of patients with SKOA at baseline and 24 month;
JSN correlation with baseline plasma IL1Ra
n ¼ 111 Mean SD Baseline IL1Ra
Medial Baseline JSW 3.65 1.34
24 month JSW 3.13 1.51
JSN 0.53 0.89 r ¼ 0.24; P¼ 0.01
Lateral Baseline JSW 5.77 1.43
24 month JSW 5.53 1.45
JSN 0.24 1.17 r ¼ 0.01; P ¼ 0.89
P values signiﬁcant at 5% alpha level are shown in bold type.medial JSW. Table VI shows a statistically signiﬁcant association of
IL1Ra with JSN. Prediction accuracies for IL1Ra to distinguish non-
progressors from “slow-progressors” (JSN > 0.2 mm/24 months)
and “fast-progressors” (JSN > 0.5 mm/24months) ranged from AUC
0.63 to 0.66 (Table VI). Additionally, in logistic regression models
after adjusting for age, gender and BMI, baseline IL1Ra retained
statistical signiﬁcance (P ¼ 0.0069e0.01) in all three groups of
progressors (Table VI). Our data indicate that elevated levels of
IL1Ra at baseline are correlated statistically signiﬁcantly with
radiographic progression as measured by medial JSN and can help
distinguish non-progressors (low plasma IL1Ra) from fast-pro-
gressors. Other protein biomarkers were measured at 18 months
(baseline specimens not available); none were associated with
radiographic severity (Table II) or progression at 24 months
(Supplemental Table 1).
BMI at baseline was also assessed in analyses of JSN at 24
months. As reported above, when assessed using binary model (by
ROC curve), Fisher partial correlation (Table IV), or dichotomized
according to median BMI (Table V), BMI did not associate with
medial JSN progression. However, Table VI shows that when
dichotomized according to JSN, BMI did associate with medial JSN
progression at 24 months. It is of interest therefore that the asso-
ciation of a given biomarker with progression may vary with the
methods by which “progression” is assessed, and hence explain
some of the disparate ﬁndings in the literature.
Causal graph analysis of medial JSN
In order to further explore interactions of clinical features and
plasma biomarkers, we performed causal graph analysis to deter-
mine the interdependence of plasma protein biomarkers, cova-
riates (BMI, age, gender), clinical markers [total WOMAC, WOMAC
sub-scores (pain, stiffness and function), VAS pain] and contin-
uous JSN. Only data for 111 patients with medial JSW > 0.0 mm
were used for modeling.
The resulting graph of application of FCI is shown in Fig. 2.
Baseline IL1Ra either plays a causal role or positively inﬂuences JSN,
or there is a hidden confounder that inﬂuences both IL1Ra and JSN.
Interestingly, the analysis also indicates a causal relation between
BMI and IL1Ra, which is ambiguous: either BMI is inﬂuencing IL1Ra,
or IL1Ra is inﬂuencing BMI, or there is a hidden confounder that
inﬂuences both BMI and IL1Ra.
Discussion
These studies demonstrate that elevation of plasma protein
IL1Ra is modestly associated with radiographic severity (KL1/2 vs
KL3/4) as well as increased risk for progression of SKOA at 24
months. In addition, the data indicate that WOMAC (total, pain,
function) and VAS pain are correlated with the severity of SKOA, as
has been reported30,31. However, in these studies neither baseline
WOMAC nor VAS pain predicted radiographic progression at 24
months.
These ﬁndings suggest that plasma IL1Ra reports increased
production of cytokines and endogenous cytokine inhibitors by
joint tissues involved in the pathophysiologic process of OA at both
its early and end stages12. It is known that IL1Ra is produced by
chondrocytes, macrophages and synovial cells following exposure
to cytokines and chemokines, such as IL-1b, TNFa and IL-6. There-
fore, we postulate that elevations of IL1Ra sufﬁcient to be detected
in plasma reﬂect joint tissues exposure to inﬂammatory cytokines.
Histologic analyses of synovial biopsies, and both contrast and non-
contrast MRI studies of knee joints, have demonstrated mild-to-
moderate synovial inﬂammation in early and end stages of dis-
ease and association with increased risk of severe OA10,13,32,33.
Table V
Association of baseline plasma IL1Ra and BMI (dichotomized by median) with JSN at 24 months in 111 patients with SKOA in the medial compartment
Biomarkers Median biomarker
level at baseline
Median JSN at 24 months in patients with baseline
biomarker level:
P Value (t-test)
 median > median
IL1Ra (pg/ml) N ¼ 110 246.65 0.36 (0.75), N ¼ 55 0.7055 (0.99), N ¼ 55 0.041
BMI N ¼ 111 26.8 0.4531 (0.27), N ¼ 57 0.6204 (1.02), N ¼ 54 0.27
IL1Ra and BMI were dichotomized based on median levels to deﬁne two groups of subjects (e.g., with biomarker above vs at or below the threshold); mean JSN values were
compared in these two subject groups using a two-sample t-test. Among the 111 completers, BMI data were available for all and IL1Ra data were available for 110.
Table VI
Relationship of plasma IL1Ra and BMI to progression of JSN at 24 months in patients with SKOA
JSN  0 vs JSN > 0 (39 vs 72) AUC Lower CI Upper CI P-value Adjusted
P-value*
JSN  0 mean (SD) JSN > 0 mean (SD) (No adjust.) Adjusted for age,
gender, BMI
IL1RA 0.63 0.53 0.74 0.007 0.042 250.84 (121.06) 354.09 (231.27) 0.004 0.012
BMI 0.59 0.47 0.69 0.066 0.39
JSN  0 vs. JSN > 0.2 (39 vs. 64) AUC Lower CI Upper CI P-value JSN  0 mean (SD) JSN > 0.2 mean (SD) (no adjust.) Age, Gender, BMI
IL1RA 0.63 0.52 0.73 0.012 0.072 250.84 (121.06) 360.15 (241.19) 0.004 0.019
BMI 0.62 0.51 0.73 0.015 0.09
JSN  0 vs. JSN > 0.5 (39 vs. 44) AUC Lower CI Upper CI P-value JSN  0 mean (SD) JSN > 0.5 mean (SD) (no adjust.) Age, Gender, BMI
IL1RA 0.66 0.54 0.78 0.004 0.024 250.84 (121.06) 375.51 (236.38) 0.002 0.007
BMI 0.60 0.48 0.73 0.048 0.29
For measuring biomarker predictivity for radiographic progression in medial knee OA, we used the area under the receiver operating characteristic (ROC) curve. The mean and
standard deviation of each biomarker is provided for each group. Generalized LinearModel (GLM)-based (logistic regression) P-values are provided after adjusting individually
and in combination for three covariates: age, gender and BMI.
P-values signiﬁcant at 5% alpha level are shown in bold. JSN, joint space narrowing; AUC, area under ROC curve.
* Adjusted using Bonferroni correction.
M. Attur et al. / Osteoarthritis and Cartilage 23 (2015) 1915e19241920Noteworthy studies from Robinson and co-workers have demon-
strated the importance of inﬂammation in both animal models and
human OA11,34. OA is a heterogeneous disease, and multiple sub-
groups or phenotypes of OA have been identiﬁed based onFig. 2. Causal analysis of baseline biomarkers along with age, gender and BMI on media
age, gender), and clinical markers (WOMAC, VAS pain) on continuous radiographic JSN ove
with a single arrow denote causality, edges with double arrows denote hidden confounderetiological and risk factor such as metabolic, traumatic, inﬂamma-
tory, and subchondral bone-driven progression of OA35,36. Our data
indicate that, in a subset of patients, inﬂammation plays a role in OA
pathology and disease progression15,37e39.l JSN. To determine the interdependence of plasma protein biomarkers covariates (BMI,
r 24 months. FCI algorithm26 was used for causal graph analysis of all variables. Edges
s, and marks (circles) on the edges denote uncertainty of causal orientation.
M. Attur et al. / Osteoarthritis and Cartilage 23 (2015) 1915e1924 1921Consistent with the IL1Ra ﬁndings reported in the present work,
multiplex cytokine analysis revealed increased inﬂammatory pro-
teins in sera of OA patients compared to controls, including IL-1b,
IL1Ra, IL-6, MCP-1, MIG, VEGF, and GM-CSF11. The novel ﬁnding in
the current study is that IL1Ra predicts radiographic JSN progres-
sion in a causal fashion. This is particularly intriguing since poly-
morphisms in the IL1RN gene have been shown to predict
radiographic severity and progression in OA40,41. We do not suggest
that IL1Ra per se promotes joint damage, but rather that its pro-
duction as an endogenous anti-inﬂammatory protein is a response
to the degree of inﬂammation within the joint. IL1Ra levels are
therefore an indirect measure of IL-1 and other cytokine activity
within joint tissues. IL1Ra is mainly produced by synovial macro-
phages, where it is induced by cytokines such as IL-1 and IL-442,
chemokines, and interferon gamma (IFN-g)43. Synovitis has been
associated with increased risk for progression of human OA; in
animals, Blom et al. have shown that depletion of synovial macro-
phages greatly reduces induction of experimental OA inmice44. Our
data are consistent with the hypothesis that plasma IL1Ra, pro-
duced by synovial macrophages, reports synovial inﬂammation,
and therefore may be useful as a prognostic biomarker reﬂecting
causal events that promote radiographic progression of SKOA.
Among the more intriguing ﬁndings of this study was the
revelation by causal graph analysis of a causal relation between
BMI, IL1Ra and SKOA progression, which remains unclear [Fig. 2].
BMI alone was associated with radiographic progression, when
progression was dichotomized according to JSN (Table VI); how-
ever, unlike IL1Ra, BMI was not associated with JSN when JSN was
assessed as a continuous variable (Table IV) or BMI dichotomized
according to median levels (Table V). Interestingly, IL1RN TGC
haplotype (rs419598/rs9005/rs315943) was associated with
radiographic progression of knee OA in the Johnston County Oste-
oarthritis Project cohort41. Consistent with the NYUHJD cohort, the
rate of progression in this populationwas not signiﬁcantly higher in
subjects with BMI greater than the median (28.5 kg/m2) compared
to those below the median. However, BMI association with pro-
gression was only evident in subjects who carried the IL1RN TGC
haplotype. Taken together, these data may suggest that the rela-
tionship between IL1Ra and JSN depends upon BMI, but the rela-
tionship is governed by genetic variations. It is also of interest that
IL1Ra has been reported to be positively correlated with BMI and
insulin resistance45, and to play a role in cholesterol excretion46.
Additionally, IL1Ra and leptin are markers of obesity47. Leptin is
shown to be elevated in obese OA patients and promotes catabolic
activities in cartilage48. In our current study we did not determine
leptin levels in plasma samples.
Thus, the data from our studies and in the literature indicate an
as-yet-undetermined interaction between IL1Ra and BMI: either
BMI is inﬂuencing IL1Ra, or IL1Ra is inﬂuencing BMI, or there is a
hidden confounder that inﬂuences both BMI and IL1Ra.
Inﬂammatory cytokines, notably IL-1b and TNFa, produced by
joint tissues in the pathogenesis of OA have attracted increased
attention. IL-1b exerts catabolic effects on chondrocyte meta-
bolism, decreasing proteoglycan collagen synthesis and increasing
aggrecan release via the induction of degradative proteases. IL-1b
also induces IL1Ra expression in chondrocytes and synovial ﬁbro-
blasts9. Richette et al. have reported OA patients with lower median
levels of IL-1b and IL1Ra in synovial ﬂuids than RA patients, and
also concluded that the ratio of IL1Ra/IL-1bwas not associated with
pain or disability in OA patients49. In addition to IL1Ra, other
markers of inﬂammation have recently been reported in OA,
including the observation that serum levels of TNFa and IL-6 in-
ﬂammatory markers associate with knee pain in older adults11,50,51.
Additionally, Kraus and associates have shown that synovial ﬂuid
IL-1b and IL-18 are associated with OA severity and progression52.Another acute phase protein, serum amyloid protein, is also
elevated in OA53. Proteomics proﬁling of synovial ﬂuid identiﬁed
three dominant pathways that are dysregulated in OA relative to
healthy controls: the acute-phase response signaling pathway,
complement pathway, and coagulation pathway54. This further
emphasizes that acute-phase response may be activated to resolve
injury (such as cartilage damage) as response to an ongoing in-
ﬂammatory process. In our studies, the other inﬂammatory protein
biomarkers studied did not predict severity or progression in SKOA.
However, we note that sufﬁcient plasma for these studies was not
available for assay until the 18-month time point. Therefore, we
cannot determine whether elevations of one or more of these
biomarkers might have predicted progression were a full 24
months of follow-up permitted. Such studies are ongoing.
We have previously reported that peripheral blood leukocytes
(PBL) in selected patients with OA are activated to express in-
ﬂammatory genes, including IL-1b, TNFa and COX-215. This obser-
vation has also been made in animal models of OA55,56. We
speculate that one explanation for the inﬂammatory plasma
signature in a subset of SKOA patients is that PBLs are activated as a
result of repeated exposure to inﬂammatory stimuli as they circu-
late through the diseased synovium and subchondral bone of
affected joints. Enhanced expression of mRNA for IL-6 and TNFa by
CD34þ hematopoietic precursor cells is shown in the bone marrow
of both OA and RA patients compared to normal marrow57. This
raises the intriguing possibility that activated PBLs observed in our
studies originate from a pool of activated precursor cells in the bone
marrow of SKOA joints.
ESCEO has recently suggested that radiographic JSN > 0.5 mm
over 2 or 3 years (fast-progressors) might be a reliable surrogate
measure for total joint replacement23. Of note, Reginster et al. have
shown in a recent large clinical trial that >30% of OA patients had
JSN > 0.5 mm over 24 months58, consistent with our data. In-
ﬂammatory biomarkers may be used to identify the subgroups
among those with clinical knee OA in whom disease progresses at
different rates. We would like to point out that, as with any other
biomarker, there is signiﬁcant overlap or distribution of IL1Ra be-
tween severity (KL1/2 vs Kl3/4) or progressors (JSN < 0.0 mm to
JSN > 0.2 or 0.5 mm) groups; nonetheless, it reaches signiﬁcance in
our studies. There are a number of limitations to this study, such as
the modest size of the cohort, and current observations will need to
be validated in other, larger cohorts. In addition, most of the plasma
cytokinemarkers other than IL1Rawere assessed at 18months only
and not also at baseline, due to the availability of adequate speci-
mens at that time point. In the current study, plasma IL-1Ra iden-
tiﬁed SKOA patients with severe disease or radiographic
progressors at a group (but not at individual) level. Future studies
will include all biomarkers at baseline to allow their evaluation at
two or more years of follow-up.
Furthermore, there is a need for improvedmethods to assess the
progression of OA, in order to understand differences among
studies, since multiple joint compartments are involved and there
are limitations to existing imaging methodologies. Radiographic
progression of knee OA has been assessed using semi-quantitative
measures of osteophytes, composite scores such as Kell-
greneLawrence grade, and quantitative or semi-quantitative
measures of JSW. Therefore, association of biomarkers with pro-
gression is dependent on multiple factors: the source (tissue),
location (blood, synovial ﬂuid) and stage and phenotype of the OA
disease.
In summary, emerging multi-modal biomarkers, including wet
(chemical, genomic or measurement of gene expression) and dry
(imaging) biomarkers, contribute to a multi-level, “systems” view
of OA and hold promise for early diagnosis and as prognostic tests
for managing osteoarthritis. Integrative analyses, which combine
M. Attur et al. / Osteoarthritis and Cartilage 23 (2015) 1915e19241922traditional statistical andmultivariate predictive and other forms of
advanced analytics, are helpful in synthesizing all available infor-
mation as demonstrated in the present work. IL1Ra can potentially
be used to identify and predict inﬂammatory knee OA phenotypes
and monitor radiographic disease progression. As elegantly
observed by Bruyere et al.39, “Decisions on the selection of appro-
priate therapy can be made considering clinical presentation, un-
derlying pathophysiology and stage of OA disease. Furthermore,
identiﬁcation of these patient proﬁles and phenotype of OA may
lead to more personalized healthcare and more targeted treatment
for osteoarthritis.” We investigated here the application of cutting-
edge causal graph techniques that have recently been shown to
have signiﬁcant de novo mechanism and pathway discovery capa-
bilities59e61; this approach has provided evidence that IL1Ra e in
an as-yet-undeﬁned interaction with BMI e predicts radiographic
medial JSN progression, and our ongoing research in a larger OAI
cohort may provide deeper understanding of the role of plasma
IL1Ra in pathophysiology of OA.
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